Archana Sah

Note to File

Archana Sah is a clinical development thought leader with extensive (30 years) experience and passion for developing medicines for patients having led and contributed to 15 FDA/EMEA drug approvals in Oncology, Immuno-Oncology, Precision Therapeutics, Rare Diseases, Metabolic Diseases and Women's Health. She has held various global positions within biotech and pharma including Genentech/Roche, Bayer Oncology, Johnson & Johnson, ICON, two Oncology biotech start ups and a Digital tech company Medable where she led Oncology TA Solutions. She is now the Founder and CEO of AS Pharma Advisors and provides strategic advisory services to several organizations in clinical development and operations and innovations in digital health technology.

She is a recognized leader/change agent passionate about bringing innovation and efficiencies within the entire clinical trial ecosystem as an advisor and speaker. She has been the co-founding chair (2019-2021) and now a member of Society for Clinical Research Sites Oncology Board and chaired the Annual Oncology Summits. She serves on the Leadership Council for Decentralized Trials and Research Alliance and has been a member of the Digital Innovation in Oncology Roundtable with DiMe. She also serves as an Advisor to American Cancer Society Cancer Action Network. She has contributed to the clinical trial sites Standardization and Harmonization with the Forum on Drug Discovery and Development, National Academy of Sciences.

This week we discuss the unique challenges of implanting DCT in oncology, the ever-present need for better interoperability, and what the next 5 years of DCT might look like.